ANI Pharmaceuticals, Inc.ANIPNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank50
3Y CAGR-16.7%
5Y CAGR+10.8%
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

3Y CAGR
-16.7%/yr
vs +4.5%/yr prior
5Y CAGR
+10.8%/yr
Recent deceleration
Acceleration
-21.2pp
Decelerating
Percentile
P50
Within normal range
vs 5Y Ago
1.7x
Solid growth
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
202527.28%
202454.39%
202330.35%
202247.16%
202129.71%
202016.37%
201926.73%
201839.53%
201713.48%
201631.54%